The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice

Journal of Korean Medical Science

Volumn 24, Issue 6, 2009, Pages 1139-1144

  Kwak, Kyung Won ^a   Kim, Sun Hee ^b   Lee, Hyun Moo ^b  

^a Korea Electric Power Research Institute (KEPRI)   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bladder urothelial carcinoma; Cytology; Fluorescence; In situ hybridization

Indexed keywords

AGED; ARTICLE; BLADDER TUMOR; CYTOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINE; UROTHELIUM;

AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE; UROTHELIUM;

EID: 75349097017     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.6.1139     Document Type: Article

References (22)

1. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990; 322: 1129-38.
2. Maier U, Simak R, Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 1995; 48: 314-7.
3. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001; 165: 600-11.
4. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 2001; 165: 1067-77.
5. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003; 169: 1975-82.
6. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003; 61: 109-18.
7. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000; 2: 116-23.
8. Zellweger T, Benz G, Cathomas G, Mihatsch MJ, Sulser T, Gasser TC, Bubendorf L. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006; 119: 1660-5.
9. Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, Sidransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271: 659-62.
10. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O'Kane DJ, Seelig SA, Lieber MM, Jenkins RB. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000; 164: 1768-75.
11. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002; 42: 547-52.
12. Marin-Aguilera M, Mengual L, Ribal MJ, Burset M, Arce Y, Ars E, Oliver A, Villavicencio H, Algaba F, Alcaraz A. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet Cytogenet 2007; 173: 131-5.
13. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002; 167: 2001-6.
14. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, Lieber M, Soloway M, Flom K. Clinical evaluation of a multitarget fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168: 1950-4.
15. Raitanen MP, Marttila T, Kaasinen E, Rintala E, Aine R, Tammela TL. Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol 2000; 163: 1689-92.
16. Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002; 167: 80-3.
17. Bhuiyan J, Akhter J, O'Kane DJ. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 2003; 331: 69-77.
18. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001; 116: 79-86.
19. Junker K, Fritsch T, Hartmann A, Schulze W, Schubert J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006; 114: 279-83.
20. Raitanen MP, Kaasinen E, Lukkarinen O, Kauppinen R, Viitanen J, Liukkonen T, Tammela TL. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer. Urology 2001; 57: 680-4.
21. Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H, Marberger M. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol 1998; 159: 265-9.
22. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, Huland H. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003; 92: 911-4.